[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"age---related-macular-degeneration-amd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:age---related-macular-degeneration-amd":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,78,122,150],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100632579","enhanced-vision-and-imaging-tests-for-enabling-treatment-trials-in-early-and-intermediate-amd-100632579",false,"NCT07515521","Enhanced Vision and Imaging Tests for Enabling Treatment Trials in Early and Intermediate AMD","EVITE-AMD","Inclusion Criteria:\n\n* Written informed consent.\n* All biological sexes and gender identities.\n* Age \\>=18 years for healthy volunteers; age \\>=55 years for participants with AMD.\n* Ability to understand German or English sufficiently for study information and procedures.\n\nAdditional Inclusion Criteria by Cohort:\n\nHealthy Volunteers:\n\n\\- No drusen \\>63 um and no subretinal drusenoid deposits in either eye.\n\nEarly AMD:\n\n\\- Study eye with drusen \\>63 um but \\\u003C125 um and no pigmentary changes.\n\nIntermediate AMD:\n\n\\- Study eye with drusen \\>125 um and\u002For pigmentary changes.\n\nExclusion Criteria:\n\n* Claustrophobia relevant to dark-adaptation procedures.\n* Hypersensitivity to indocyanine green or sodium iodide, iodine allergy, or hyperthyroidism.\n* Known pregnancy.\n* Study eye history of ocular surgery other than cataract surgery, YAG capsulotomy, or laser retinopexy.\n* Ocular disease in the study eye that could affect visual function testing in the opinion of the investigators.\n* Medical conditions or planned operations that could interfere with follow-up.\n* Inability to comply with study procedures or insufficient language skills in the study language.\n* Inability to provide informed consent.",true,"ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","OBSERVATIONAL","This monocentric prospective longitudinal observational study will validate fundus-tracked dark adaptometry as an endpoint for future treatment trials in early and intermediate age-related macular degeneration (AMD). The study will characterize normative cone- and rod-mediated dark adaptation parameters in healthy volunteers, assess test-retest reliability, quantify sensitivity to change over time, evaluate diagnostic and prognostic validity against AMD stage and structural progression, and investigate imaging-, biomarker-, and genetics-based determinants of impaired dark adaptation.",[25],"Age - Related Macular Degeneration (AMD)",[27],"AMD","RECRUITING","2026-03-31",{"date":31,"type":32},"2026-04-07","ACTUAL",{"date":34,"type":32},"2026-02-15",{"date":36,"type":21},"2028-12-15",{"name":38,"class":39},"Maximilian Pfau","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100605581","international-study-of-the-sing-imt-prosthesis-in-pseudophakic-patients-with-stable-moderate-to-profound-bilateral-central-vision-impairment-due-to-advanced-amd--perspective-study-100605581","NCT07164378","International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Central vIsion Impairment Due to adVancEd AMD \u002F PERSPECTIVE Study","Prospective, MulticEnter, Randomized, International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Central vIsion Impairment Due to adVancEd AMD \u002F PERSPECTIVE Study","PERSPECTIVE","Inclusion Criteria:\n\n1. Be 55 years of age or older;\n2. Subjects with late-stage AMD; Have retinal findings of geographic atrophy or disciform scar with foveal involvement in both eyes;\n3. Had cataract surgery (with IOL implantation in both eyes) at least 6 months prior to enrollment;\n4. BCDVA no better than 20\u002F80 and no worse than 20\u002F800 in both eyes.\n5. Have adequate peripheral vision in the eye not scheduled for surgery, assessed by observation of ambulation.\n6. Achieve using the ETS, at least 2-lines (10 or more letters) improvement in distance on the ETDRS chart in the eye scheduled for surgery.\n7. Have an Anterior chambre depth (ACD) of at least 2.5 mm, measured from endothelium, in both eyes.\n8. Have an ECD of at least 1600 cells per square mm in both eyes.\n9. Be willing to participate in a postoperative training program for the use of the SING IMT™ implant.\n10. Review and sign the IEC approved Informed Consent Form (ICF) prior to any clinical investigation-related procedures being performed.\n11. Patient is registered with the national social security or equivalent in the country where consent is signed\n12. A woman is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n13, Not a woman of childbearing potential (WOCBP): A WOCBP who agrees to follow contraceptive guidance starting with the screening visit and through to the end of the study\n\nExclusion Criteria:\n\nA. Bilateral Ocular Conditions (affecting both eyes):\n\n1. Evidence of active choroidal neovascularization (CNV), or treatment for CNV within the past six (6) months.\n2. Diabetic retinopathy.\n3. Retinal vascular diseases.\n4. History of retinal detachment.\n5. Retinitis pigmentosa.\n6. Intraocular tumor.\n7. Corneal Stromal or Endothelial Dystrophies (for example corneal guttata)Corneal guttata.\n8. Patient predisposing to eye rubbing\n\n   B. Surgical Eye Conditions:\n9. Narrow angle (i.e., \\\u003C Schaffer grade 2).\n10. Axial length \\\u003C21 mm or \\>26 mm.\n11. Any history or current ocular or intraocular inflammation, infection, or edema, including but not limited to: - Uveitis, iritis, keratitis, keratouveitis, microbial keratoconjunctivitis.\n12. Plate haptic shape IOL implanted.\n13. Vitrectomized eye.\n14. Zonular weakness, instability, presence of pseudoexfoliation.\n15. Iris abnormalities, including but not limited to: Transillumination defects (e.g., pigment dispersion syndrome), aniridia, iris neovascularization.\n16. Any IOL already implanted in the sulcus.\n17. Presence of toric or multifocal IOL types.\n18. Optic Nerve Disease\n\n    C. Systemic or Other General Conditions:\n19. A history of steroid-induced IOP elevation uncontrolled, glaucoma, or preoperative IOP \\>22 mmHg.\n20. Known sensitivity to post-operative medications.\n21. Significant communication impairment or severe neurological disorders.\n22. Administration of any investigational product within 30 days prior to enrolment or planned participation in another clinical investigation during this study.\n23. Any condition or situation that, in the opinion of the investigator, may:\n\n    * Put the subject at significant risk,\n    * Confound the clinical investigation results, or\n    * Interfere significantly with the subject's participation in the study.\n24. Individuals under legal care (e.g., incarcerated patients or those under legal guardianship) who are unable to understand and provide informed consent.","55 Years",{"count":51,"type":21},44,"INTERVENTIONAL",[54],"NA","This study aims to expand the CE mark IFU of the SING IMT™ to pseudophakic (patients with an intraocular lents) patients with late stage of AMD (Age-Related Macular Degeneration) and bilateral central vision impairment. This randomized, international, multicenter study will evaluate the safety and efficacy of the device in this patient group. Findings will support regulatory submissions, clinical decision-making, and potential label expansion.",[25],[58,27,59,60,61,62,63,64,65,66],"Sulcus","Age-related Macular Degeneration","IOL","Intra-Ocular Lens","Pseudophakic","Samsara Vision","Add-on","SINGIMT","lens-exchange","2026-03-17",{"date":69,"type":32},"2026-03-20",{"date":71,"type":32},"2025-09-23",{"date":73,"type":21},"2027-04-30",{"name":75,"class":76},"VisionCare, Inc.","INDUSTRY",12,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":88,"conditions":89,"keywords":105,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":4},"100615866","wide-field-octa-in-ocular-diseases-100615866","NCT07298174","Wide Field OCTA in Ocular Diseases","Wide Field OCTA in Ocular Diseases: a Prospective Observational Study of the Clinical Impact of Wide Field OCTA in Ocular Disease.","WOOD-2025","Inclusion Criteria:\n\n* Age \\> 18 years\n* Both genders\n* Confirmed diagnosis of one of the above diseases\n* Age-related macular degeneration\n* Diabetic retinopathy\n* Myopia\n* Pachychoroid spectrum disease\n* Inherited retinal dystrophy\n* Uveitis\n* Dry eye\n* Visual acuity of at least 1\u002F20\n* Signed informed consent for the participation to the trial.\n\nExclusion Criteria:\n\n* Media opacities\n* Any other eye or systemic condition that may irreversibly impair the results of the study\n* Surgery in the eye in the study, including cataract extraction, in the three months prior to recruitment",{"count":87,"type":21},200,"The main retinal diseases, whether or not associated with specific mutations genetic, cause progressive degeneration of vascular retinal structures and not vascular, resulting in decreased visual function. Often, such diseases affect the noblest part of the retina, called macula. Many retinal diseases can be complicated by choroidal neovascularization which causes frequent bleeding and fluid leakage that accumulates in the subretinal and intraretinal spaces. Although the investigators know many details of each disease affecting the retina, very often the correct diagnostic framework can be complicated, given the presence of morphological elements common to the different pathologies. Similarly, predicting the effect of treatment and the patient's outcome is a constant challenge for the ophthalmologists. Most of the current research has been focused on the assessment of vascular alterations localized in the macula. However, growing evidence highlight the importance of peripheral vascular changes on the outcome of retinal diseases. These changes can be detected only be wide field OCT devices.\n\nOn the other hand, ocular inflammation and hyperemia represent major assessments in anterior segment disorders, such as dry eye disease. The current grading systems of ocular inflammation, redness and hyperemia are characterized by several limitations, thus making these evaluations still mainly confined to the subjective assessment performed by the ophthalmologist. However, the new generation OCT devices may include also an anterior segment module which can reconstruct anterior segment vessels, non-invasively, using the same technology described for retinal diseases.\n\nThe main goal of the study is to evaluate the diagnostic contribution of a new generation wide field OCTA device in ocular diseases, which has recently received CE marking. In particular, the investigators will evaluate this new generation device both in retinal and anterior segments diseases, testing for common points and differences with the standard of care non-invasive diagnostic devices. Secondary outcomes include the assessment of the correlation between the patient's visual function (visual acuity) and morphological changes (standard of care imaging assessment) highlighted by the wide field OCT device, with particular attention to microstructural differences between major ocular diseases and the possible development of non-invasive biomarkers, useful for the diagnosis and follow-up of such pathologies.",[25,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104],"Diabetic Macular Edema","Diabetic Retinopathy","Myopia","Inherited Retinal Disease","Stargardt Disease","Retinitis Pigmentosa (RP)","Best Disease","Geographic Atrophy","Macular Neovascularisation","Ocular Surface Disease","Central Serous Choroidopathy","Pachychoroid Disease","Uveitis","Vitreoretinal Disease","Retinal Vein Occlusion",[106,107,108,109,110,111],"wide-field octa","multimodal retinal imaging","quantitative imaging","retinal disease","macular disease","ocular surface disease","NOT_YET_RECRUITING","2025-12-22",{"date":115,"type":32},"2025-12-30",{"date":117,"type":21},"2026-01",{"date":119,"type":21},"2028-05",{"name":121,"class":39},"IRCCS San Raffaele",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":52,"phases":131,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":149},"100566766","phase-2-study-to-evaluate-efficacy-and-safety-of-onl1204-in-patients-with-ga-associated-with-amd-100566766","NCT06659445","Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD","A Phase 2 Multicenter, Randomized, Double-masked, Sham-controlled, Reference-arm Study to Evaluate Efficacy and Safety of ONL1204 in Patients With Geographic Atrophy (GA) Associated With Age-related Macular Degeneration (AMD)","Inclusion Criteria:\n\n1. 55 years of age or older at Screening.\n2. Able and willing to give informed consent and attend study visits.\n3. Women or intersex individuals must be willing to use 2 forms of effective contraception during the study and for at least 90 days following the last dose of study drug, be postmenopausal for at least 12 months prior to study entry, or surgically sterile. If of childbearing potential, a negative urine pregnancy test is required at Screening and prior to the administration of study drug at each visit.\n4. Men or intersex individuals with partners of childbearing potential must be willing to use permissible methods of contraception and refrain from sperm donation during the study and for at least 90 days following the last dose of study drug.\n5. If currently using Age-related Eye Disease Study 2 (AREDS, AREDS2, or similar nutraceutical therapy at Screening, patient must be willing to continue use for the duration of the study. If not currently using AREDS2 or similar, patient must be willing to continue not to use therapy for the duration of the study. Patient must agree to choose either approach.\n\n   Study Eye Inclusion Criteria:\n6. BCVA of 24 letters or more using ETDRS charts in the study eye at Screening.\n7. Intraocular pressure (IOP) of 22 mmHg or lower in the study eye at Screening.\n\n   The GA lesion must meet all the following criteria:\n8. Non-foveal GA associated with AMD without eMNV in the study eye per Investigator's evaluation and as confirmed by the central RC.\n9. GA ≥0.85 disc area (DA) (2.125 mm2) and ≤8.05 DA (20.125 mm2) in the study eye as confirmed by the central RC.\n10. If GA in the study eye is multifocal, at least 1 focal lesion must be ≥0.425 DA (1.063 mm2) as confirmed by the central RC.\n11. Non-foveal GA (GA lesion up to the fovea, but not subfoveal) with the lesion's closest border 1725 microns or less from the foveal center in the study eye, as confirmed by the central RC.\n12. The entire GA lesion in the study eye must be completely visualized on the macula-centered FAF image, must be able to be imaged in its entirety, and must not be contiguous with any areas of peripapillary atrophy per the Investigator's evaluation and as confirmed by the central RC.\n13. A pattern of hyper-autofluorescence in the junctional zone of GA in the study eye must be present as confirmed by the central RC.\n\n    Fellow Eye Inclusion Criterion:\n14. BCVA of 19 letters or more using ETDRS charts in the fellow eye at Screening.\n\nExclusion Criteria:\n\n1. Current or planned participation in another investigational clinical study or use of any other investigational drugs or devices at least 6 months prior to enrollment or during the study period without prior written Sponsor approval.\n2. Previous ophthalmic disease gene therapy or planned participation in any gene therapy clinical study during the study period.\n3. Current or planned use of systemic complement inhibitors during the study period.\n4. Any ocular or systemic condition that, in the opinion of the Investigator, makes the patient unsuitable for treatment with an investigational drug or that would compromise the safety or efficacy assessments of the study.\n5. Treatment with any ocular or systemic medication that is known to be toxic to the lens, retina, or optic nerve (including, but not limited to, aminoglycosides, vancomycin, hydroxychloroquine, interferon, tacrolimus, cisplatin, bis-chloroethyl nitrosourea, carmustine, ethambutol, and tamoxifen) within 90 days prior to Screening or anticipated during the study period.\n6. Any previous treatment of pentosan polysulfate (Elmiron®) is exclusionary.\n7. Known allergy to fluorescein, povidone iodine, or any ingredients of the study drug or avacincaptad pegol intravitreal solution.\n8. Individuals who are currently pregnant, planning to become pregnant, or are nursing at Screening or during the study period.\n\n   Study Eye Exclusion Criteria:\n9. Active ocular or periocular infection in the study eye.\n10. Any contraindication to an IVT injection in the study eye.\n11. Any media opacity in the study eye that limits visual acuity, clinical visualization of the retina, or retinal imaging as determined by the Investigator.\n12. Previous IVT pharmaceutical treatment in the study eye with any agent except Food and Drug Administration (FDA)-approved complement inhibitors and treatment with FDA-approved complement inhibitors within 12 weeks prior to Screening.\n13. Any history of incisional retinal surgery in the study eye including but not limited to scleral buckle or vitrectomy. (Retinal laser for a tear or hole 3 months or more prior to Screening is not exclusionary).\n14. History of incisional glaucoma surgery including trabeculectomy, tube shunt, or minimally invasive glaucoma surgery in the study eye. (Glaucoma laser procedures performed at least 6 months prior to Screening are not exclusionary).\n15. Yttrium aluminum garnet capsulotomy in the study eye within 1 month prior to Screening.\n16. Cataract surgery in the study eye planned or expected during the study period.\n17. Aphakia with absence of the posterior capsule in the study eye. (Pseudophakia with an open posterior capsule is not exclusionary).\n18. Any current evidence or history in the study eye of exudative (\"wet\") AMD, including any RPE rips or evidence of actively leaking neovascularization anywhere in the retina based on the FA or SD-OCT as assessed per the Investigator's evaluation and confirmed by the central RC.\n19. Any clinically significant retinal disease other than AMD except benign degenerative conditions (eg, Cobblestone degeneration) in the study eye.\n20. Intraocular surgery in the study eye (including lens replacement surgery) within 3 months prior to Screening. See Exclusion Criteria 12 and 13 pertaining to retinal and glaucoma surgery, respectively.\n21. Previous therapeutic radiation (including transpupillary thermotherapy, photodynamic therapy, or external-beam) in the region of the study eye.\n\n    Fellow Eye Exclusion Criterion:\n22. Planned or expected IVT injection in the fellow eye for treatment of GA with agents other than FDA-approved complement inhibitors (pegcetacoplan or avacincaptad pegol IVT solution \\[Izervay™\\]) during the study period.\n\n    Either Eye Exclusion Criteria:\n23. Active intraocular inflammation in either eye or a history of uveitis or endophthalmitis in either eye.\n24. GA in either eye due to causes other than AMD.\n25. Any ophthalmic condition in either eye that is likely to require surgery during the study period.",{"count":130,"type":21},324,[132],"PHASE2","The purpose of this study is to collect efficacy and safety information of intravitreal injection for 3 experimental arms, including 2 dose levels of ONL1204 and 2 treatment frequencies in patients with GA associated with AMD.\n\nGA associated with AMD is one of the world's leading causes of visual disability and legal blindness globally. Associated with aging, cigarette smoking, obesity, diets low in certain nutrients, a lifestyle related to cardiac risk, and a growing list of genetic factors, AMD is becoming an increasingly prevalent public health concern, especially as the global population ages. ONL1204 is a first-in-class inhibitor of fragment apoptosis stimulator receptor-mediated cell death that has demonstrated protection of multiple retinal cell types in numerous preclinical models of retinal disease, including models of dry AMD.",[135,25],"Geographic Atrophy (GA)",[137,138,135,139],"Phase 2","ONL1204","Age-related Macular Degeneration (AMD)","2025-12-03",{"date":142,"type":32},"2025-12-05",{"date":144,"type":32},"2025-10-28",{"date":146,"type":21},"2028-11",{"name":148,"class":76},"ONL Therapeutics",28,{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":156,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":52,"phases":160,"briefSummary":162,"conditions":163,"keywords":164,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":4},"100602255","early-phase-1-effect-of-fus-subcutaneous-needling-for-age-related-macular-degeneration-100602255","NCT07121127","Effect of Fu's Subcutaneous Needling for Age-related Macular Degeneration","Inclusion Criteria:\n\n（ 1 ） Age between 50 and 85 years old with no gender restrictions （ 2 ） Meets the diagnostic criteria for dry age-related macular degeneration (AMD) as outlined in the 2023 Chinese Clinical Practice Guidelines for Age-Related Macular Degeneration （ 3 ） Both monocular and binocular cases of dry AMD are included. For patients with bilateral lesions the experimental group is based on the patient's preferred eye (if both eyes are preferred the average of the data collected from both eyes is included in the analysis) （ 4 ） Participants must voluntarily consent and sign an informed consent form and be willing to cooperate with follow-up visits.\n\nExclusion Criteria:\n\n（ 1 ） Serious eye diseases that significantly affect the condition of the fundus excluding dry macular degeneration including fundus lesions such as fundus hemorrhage and wet macular degeneration; or concomitant eye diseases requiring immediate treatment such as acute glaucoma; severe opacity of the refractive media such as mature cataracts （ 2 ） In distance vision testing the patient cannot discern the direction of the largest character at a distance of 1 meter from the distance vision chart （ 3 ） Participants who have undergone eye surgery within the past six months （ 4 ） Participants with non-ophthalmic conditions that may severely affect vision such as large-area cerebral infarction cerebral hemorrhage diabetes thyroid eye disease vitamin A deficiency or Sjögren's syndrome （ 5 ） Pregnant or lactating women （ 6 ） Participants with severe anemia renal failure acute phase of cardiovascular disease implanted cardiac pacemaker thrombocytopenia or other hematological conditions with a high risk of severe subcutaneous bleeding or requiring skin puncture （ 7 ） Participants who have taken medications or consumed foods that affect ocular blood supply within the past week such as caffeine atropine or other treatments for macular degeneration （ 8 ） Participants who require contact lenses.","50 Years","85 Years",{"count":159,"type":21},38,[161],"EARLY_PHASE1","This pilot randomized controlled trial aims to evaluate the efficacy and safety of FSN in improving symptoms in patients with dAMD.38 eligible participants will be recruited and randomly assign them in a 1:1 ratio to the FSN group and the control group. Throughout the study, both groups will take oral vitamin C and vitamin E supplements for a total of 28 days. Participants in the FSN group will receive four treatment sessions over two weeks. Both groups will be assessed at the end of the FSN treating period during the mid-study period, with ocular blood flow dynamics measured using OCTA, followed by a two-week follow-up. The primary outcome of this trial is the change in visual acuity from baseline to week 2, with secondary outcomes including visual field, visual function scale, macular thickness, central avascular zone area vascular density, and choroidal thickness.",[25],[165,166,167],"Fu's subcutaneous needling","age-related macular degeneration","OCTA","2025-08-12",{"date":170,"type":32},"2025-08-13",{"date":172,"type":21},"2026-07-07",{"date":174,"type":21},"2030-03-09",{"name":176,"class":39},"Zhiming Yan"]